Johnson Investment Counsel’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.4M Sell
247,483
-326,923
-57% -$26.4M 0.14% 120
2026
Q1
$49.8M Sell
574,406
-3,130
-0.5% -$300K 0.4% 68
2025
Q4
$55.5M Sell
577,536
-12,740
-2% -$1.24M 0.45% 63
2025
Q3
$56.2M Sell
590,276
-5,920
-1% -$544K 0.47% 63
2025
Q2
$52M Buy
596,196
+21,246
+4% +$1.8M 0.47% 62
2025
Q1
$51.7M Sell
574,950
-8,948
-2% -$801K 0.5% 58
2024
Q4
$46.6M Sell
583,898
-33,237
-5% -$2.88M 0.45% 66
2024
Q3
$55.6M Sell
617,135
-21,327
-3% -$1.79M 0.55% 55
2024
Q2
$50.3M Sell
638,462
-10,271
-2% -$842K 0.53% 58
2024
Q1
$56.5M Buy
648,733
+7,464
+1% +$637K 0.61% 55
2023
Q4
$52.8M Sell
641,269
-73,121
-10% -$5.57M 0.62% 52
2023
Q3
$56M Buy
714,390
+23,234
+3% +$1.94M 0.72% 49
2023
Q2
$60.9M Sell
691,156
-9,135
-1% -$786K 0.76% 47
2023
Q1
$56.5M Buy
700,291
+4,134
+0.6% +$337K 0.75% 44
2022
Q4
$54.1M Buy
696,157
+15,458
+2% +$1.25M 0.74% 45
2022
Q3
$55M Buy
680,699
+7,217
+1% +$649K 0.81% 42
2022
Q2
$60.4M Buy
673,482
+6,434
+1% +$652K 0.86% 43
2022
Q1
$74.4M Buy
667,048
+48,603
+8% +$5.13M 0.92% 36
2021
Q4
$64.4M Buy
618,445
+28,484
+5% +$3.3M 0.79% 43
2021
Q3
$74.3M Buy
589,961
+14,896
+3% +$1.93M 1% 31
2021
Q2
$71.7M Buy
575,065
+25,270
+5% +$3.17M 0.99% 32
2021
Q1
$65.3M Buy
549,795
+12,769
+2% +$1.5M 0.98% 33
2020
Q4
$63.2M Buy
537,026
+12,166
+2% +$1.34M 1.05% 27
2020
Q3
$54.8M Sell
524,860
-2,522
-0.5% -$253K 1.02% 31
2020
Q2
$48.7M Sell
527,382
-479,787
-48% -$46M 0.98% 31
2020
Q1
$103M Buy
1,007,169
+504,051
+100% +$53.6M 2.28% 8
2019
Q4
$57.3M Sell
503,118
-4,392
-0.9% -$482K 1.08% 23
2019
Q3
$55.4M Sell
507,510
-2,850
-0.6% -$297K 1.1% 24
2019
Q2
$49.7M Buy
510,360
+9,293
+2% +$848K 1.03% 29
2019
Q1
$45.6M Buy
501,067
+21,906
+5% +$1.96M 0.97% 30
2018
Q4
$43.6M Sell
479,161
-7,164
-1% -$669K 1.06% 21
2018
Q3
$47.8M Sell
486,325
-98,136
-17% -$9.07M 1.06% 24
2018
Q2
$50M Sell
584,461
-16,368
-3% -$1.37M 1.23% 18
2018
Q1
$48.2M Buy
600,829
+30,297
+5% +$2.5M 1.23% 17
2017
Q4
$46.1M Buy
570,532
+6,842
+1% +$548K 1.15% 21
2017
Q3
$43.8M Buy
563,690
+13,152
+2% +$1.09M 1.16% 17
2017
Q2
$48.9M Buy
550,538
+52,203
+10% +$4.4M 1.36% 14
2017
Q1
$40.1M Buy
498,335
+71,891
+17% +$5.62M 1.16% 15
2016
Q4
$30.4M Buy
426,444
+84,184
+25% +$6.61M 0.93% 35
2016
Q3
$29.6M Buy
342,260
+68,529
+25% +$5.97M 0.95% 29
2016
Q2
$23.8M Buy
273,731
+138,601
+103% +$11.2M 0.78% 41
2016
Q1
$10.1M Buy
135,130
+114,256
+547% +$8.61M 0.35% 64
2015
Q4
$1.6M Buy
20,874
+178
+0.9% +$13.4K 0.06% 176
2015
Q3
$1.39M Buy
+20,696
New +$1.52M 0.05% 188
2014
Q4
Sell
-17,575
Closed -$1.09M 570
2014
Q3
$1.09M Sell
17,575
-959
-5% -$61K 0.04% 205
2014
Q2
$1.18M Buy
18,534
+3,600
+24% +$219K 0.04% 176
2014
Q1
$919K Buy
14,934
+1,511
+11% +$88K 0.03% 203
2013
Q4
$770K Buy
13,423
+185
+1% +$10.5K 0.03% 223
2013
Q3
$704K Buy
13,238
+221
+2% +$11.9K 0.03% 219
2013
Q2
$669K Buy
+13,017
New +$643K 0.03% 213

Other funds holding MDT

Johnson Investment Counsel's MDT Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Medtronic (MDT) stake by 57% in Q2 2026, selling an estimated $26.4M and leaving 247,483 shares worth $19.4M. The position accounts for 0.14% of the portfolio, ranked #120.

Johnson Investment Counsel first reported a position in MDT in Q2 2013 and has held it in 50 quarters since. The position peaked at $103M in Q1 2020. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Johnson Investment Counsel held 247,483 shares of Medtronic worth $19.4M as of Q2 2026.
  • Johnson Investment Counsel sold 326,923 Medtronic shares in Q2 2026, an estimated $26.4M.
  • Medtronic made up 0.14% of Johnson Investment Counsel's portfolio in Q2 2026, its #120 holding.
  • Johnson Investment Counsel first reported a position in Medtronic in Q2 2013 and has held it in 50 quarters since.
  • Johnson Investment Counsel's Medtronic position peaked at $103M in Q1 2020.
  • 2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.